CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that the Company and its subsidiaries have entered into a new, five-year credit agreement with Perceptive Credit Holdings IV, LP (“Perceptive”), an affiliate of Perceptive Advisors.

佛罗里达州CLEARWATER（商业电信）-Apyx医疗公司（纳斯达克股票代码：Apyx）（“公司”），专有氦等离子体和射频技术的制造商以Renuvion®销售和销售，今天宣布该公司及其子公司已与Perceptive Credition IV，LP（“Perceptive”）签订了一项新的五年信贷协议，感知顾问的附属机构。

The Perceptive Credit Agreement provides for a facility of up to $45 million in senior secured term loans, with an initial loan of $37.5 million fully drawn at closing..

感知信用协议规定最高可获得4500万美元的高级担保期贷款，首次贷款总额为3750万美元。。

“We are excited to announce this new debt facility with Perceptive Advisors,” said Charlie Goodwin, President and Chief Executive Officer. “This new facility provides Apyx Medical with access to additional capital – and at more attractive terms overall – than our prior agreement, significantly strengthening our balance sheet and enhancing our financial flexibility.”.

总统兼首席执行官查理·古德温（Charlie Goodwin）说：“我们很高兴与有同情心的顾问一起宣布这项新债务。“与我们之前的协议相比，这家新设施为Apyx Medical提供了额外资金-整体而言更具吸引力，显着加强了我们的资产负债表并增强了我们的财务灵活性。”。

“We are excited to partner with Apyx Medical and believe that Renuvion will be a formidable product in the market as the company executes on its strategy,” said Sam Chawla, Portfolio Manager of Perceptive Advisors.

“我们很高兴与Apyx Medical合作，并相信随着公司对其战略的执行，Renuvion将成为市场上一个强大的产品，”Perceptive Advisors组合经理Sam Chawla说。

The Perceptive credit facility matures on November 8, 2028 and includes an initial loan of $37.5 million and a delayed draw loan of $7.5 million. The initial loan of $37.5 million was fully funded on November 8, 2023, with approximately $11.0 million of the proceeds used to satisfy all obligations under the Company’s MidCap credit agreement, in addition to approximately $2.5 million of transaction fees and other expenses incurred in connection with the Perceptive Credit Agreement.

感知信贷机构于2028年11月8日成熟，包括初始贷款3750万美元和延迟贷款750万美元。最初的3750万美元贷款于2023年11月8日全额资助，其中约1100万美元用于履行本公司MidCap信用协议下的所有义务，此外还有约250万美元的交易费和其他相关费用。与感知信用协议。

The delayed draw loan can be drawn at the Company’s option until December 31, 2024, upon satisfaction of certain conditions and covenants, including, but not limited to, the achievement of a minimum revenue target..

在满足某些条件和契约（包括但不限于实现最低收入目标）后，延迟提取贷款可根据公司的期权提取至2024年12月31日。。

The initial loan and delayed draw loan bear interest at a floating rate based on one-month SOFR, subject to a floor of 5.0%, plus 7.0%. The Perceptive Credit Agreement provides for 48 months of interest-only payments. Subsequent to the interest-only period, the outstanding principal amount of the loans is repayable in monthly payments of 3.0% of the outstanding balance on the payment date.

初始贷款和延迟提取贷款按一个月SOFR的浮动利率承担利息，最高限额为5.0%，最高限额为7.0%。感知信用协议仅提供48个月的利息付款。在仅利息期之后，该贷款的未偿还本金额应在支付日期每月支付未偿还余额的3.0%时偿还。

All remaining outstanding principal, together with all accrued and unpaid interest, is due at maturity. The loans may be voluntarily prepaid in full, or in part, at any time, subject to terms and conditions set forth in the Perceptive Credit Agreement. Additionally, the loans are subject to mandatory prepayment obligations, pursuant to the terms of the Perceptive Credit Agreement.

所有剩余的未偿还委托人，以及所有应计和未付利息，均已到期。根据感知信用协议中规定的条款和条件，贷款可以随时全部或部分自愿预付。此外，根据感知信用协议的条款，贷款受制于强制性预付款义务。

The obligations under the Perceptive credit facility are secured by first priority liens on substantially all of the assets of the Company..

感知信用机构下的义务由公司基本上所有资产的优先权授予担保。。

In connection with the Company’s initial loan under the Perceptive Credit Agreement, the Company issued Perceptive warrants to purchase up to 1,250,000 shares of its common stock, par value $0.001, with an exercise price of $2.43 per share. Upon the issuance of the delayed draw loan, if applicable, the Company will issue Perceptive warrants to purchase up to 250,000 shares of its common stock, par value $0.001, with an exercise price of equal to the 10-day volume weighted average sale price from the preceding business day..

关于本公司根据感知信用协议提供的初始贷款，本公司发布感知认股权证，购买普通股最多1250000股，平均价值为0.001美元，行使价为每股2.43美元。在发出延迟抽签贷款后，如适用，本公司将发出感知认股权证，购买最多250000股普通股股份，平均价值为0.001美元，行使价等于10天加权平均销售价。前一个工作日。。

Craig-Hallum served as financial advisor to the Company on the transaction. Additional detail regarding the foregoing financing is set forth in the Company’s Current Report on Form 8-K, to be filed with the U.S. Securities and Exchange Commission.

Craig Hallum在该交易中担任该公司的财务顾问。有关上述融资的更多详细信息，请参阅本公司当前的表格8-K报告，并将提交给美国证券交易委员会。

About Apyx Medical Corporation:

关于Apyx医疗公司：

Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Technology products marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results.

Apyx Medical Corporation是一家先进的能源技术公司，热衷于通过创新产品提升人们的生活，包括其在整容手术市场以Renuvion销售和销售的氦等离子体技术产品以及医院外科市场的J-Plasma®。Renuvion和J-Plasma为外科医生提供了独特的能力，可以为组织提供可控的热量，以达到预期的效果。

The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com..

该公司还通过与其他医疗设备制造商的OEM协议，利用其丰富的专业知识和数十年的独特波形经验。有关公司及其产品的更多信息，请参阅Apyx Medical Corporation网站www.ApyxMedical.com。。

About Perceptive Advisors:

关于感知顾问：

Founded in 1999, Perceptive Advisors is a leading healthcare focused investment firm with approximately $9.5 billion of regulatory assets under management. Since inception, Perceptive Advisors has focused on supporting progress in the life sciences industry by identifying opportunities and directing financial resources toward the most promising technologies in modern healthcare.

Perceptive Advisors成立于1999年，是一家领先的医疗保健投资公司，管理着约95亿美元的监管资产。自成立以来，Perceptive Advisors一直致力于通过识别机会并将财政资源导向现代医疗保健领域最有前途的技术来支持生命科学行业的进步。

For more information about Perceptive, visit www.perceptivelife.com..

有关Perceptive的更多信息，请访问www.perceptivelife.com。。

Cautionary Statement on Forward-Looking Statements:

关于前瞻性声明的警示性声明：

Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved..

本版本中讨论的某些事项以及本公司代表不时发表的口头陈述可能构成1995年“私人证券诉讼改革法”和“联邦证券法”含义范围内的前瞻性陈述。虽然本公司认为此类前瞻性陈述所反映的预期是基于合理的假设，但不能保证其预期会实现。。

All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including but not limited to, projections of net revenue, margins, expenses, net earnings, net earnings per share, or other financial items; projections or assumptions concerning the possible receipt by the Company of any regulatory approvals from any government agency or instrumentality including but not limited to the U.S.

除历史事实陈述外的所有陈述均为可被视为前瞻性陈述的陈述，包括但不限于净收入，利润率，支出，净收益，单位净收益或其他财务项目的预测；关于公司可能收到任何政府机构或工具的任何监管批准的预测或假设，包括但不限于美国。

Food and Drug Administration (the “FDA”), supply chain disruptions, component shortages, manufacturing disruptions or logistics challenges; or macroeconomic or geopolitical matters and the impact of those matters on the Company’s financial performance..

食品和药物管理局（“FDA”），供应链中断，组件短缺，制造中断或物流挑战；或宏观经济或地缘政治事务以及这些事项对公司财务业绩的影响。。

Forward-looking statements and information are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause the Company’s actual results to differ materially and that could impact the Company and the statements contained in this release include but are not limited to risks, uncertainties and assumptions relating to the regulatory environment in which the Company is subject to, including the Company’s ability to gain requisite approvals for its products from the FDA and other governmental and regulatory bodies, both domestically and internationally; the impact of the March 14, 2022 FDA Safety Communication on our business and operations; sudden or extreme volatility in commodity prices and availability, including supply chain disruptions; changes in general economic, business or demographic conditions or trends; changes in and effects of the geopolitical environment; liabilities and costs which the Company may incur from pending or threatened litigations, claims, disputes or investigations; and other risks that are described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and the Company’s other filings with the Securities and Exchange Commission.

前瞻性陈述和信息受到某些风险，趋势和不确定性的影响，可能导致实际结果与预期结果大不相同。许多这些因素超出了公司控制或预测的能力。可能导致本公司实际结果出现重大差异并可能影响本公司的重要因素本版本中包含的声明包括但不限于与本公司所属监管环境相关的风险，不确定性和假设，包括公司能够在国内和国际上获得FDA和其他政府和监管机构对其产品的必要批准；2022年3月14日FDA安全沟通对我们业务和运营的影响；商品价格和可用性突然或极端波动，包括供应链中断；一般经济，商业或人口状况或趋势的变化；地缘政治环境的变化和影响；本公司因未决或受威胁的诉讼，索赔，争议或调查可能产生的责任和费用；以及本公司截至2022年12月31日止财政年度10-K年度报告中描述的其他风险以及本公司与证券交易委员会的其他文件。

For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise..

对于本版本中的前瞻性声明，本公司要求保护安全港，以获得1995年“私人证券诉讼改革法”中包含的前瞻性声明。无论是由于新信息，未来事件还是其他原因，本公司均无义务更新或补充任何前瞻性声明。。